ZA200503306B - Fused azole-purimidine derivatives - Google Patents
Fused azole-purimidine derivatives Download PDFInfo
- Publication number
- ZA200503306B ZA200503306B ZA200503306A ZA200503306A ZA200503306B ZA 200503306 B ZA200503306 B ZA 200503306B ZA 200503306 A ZA200503306 A ZA 200503306A ZA 200503306 A ZA200503306 A ZA 200503306A ZA 200503306 B ZA200503306 B ZA 200503306B
- Authority
- ZA
- South Africa
- Prior art keywords
- amino
- optionally substituted
- alkyl
- salkyl
- hydroxy
- Prior art date
Links
- -1 nitro, hydroxy, cyano, carboxy, amino Chemical group 0.000 claims description 226
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 218
- 125000000217 alkyl group Chemical group 0.000 claims description 177
- 229910052736 halogen Inorganic materials 0.000 claims description 71
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 61
- 125000003545 alkoxy group Chemical group 0.000 claims description 57
- 229910052739 hydrogen Inorganic materials 0.000 claims description 56
- 239000001257 hydrogen Substances 0.000 claims description 56
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 39
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 37
- 150000002367 halogens Chemical class 0.000 claims description 34
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 27
- 125000004076 pyridyl group Chemical group 0.000 claims description 25
- 125000004193 piperazinyl group Chemical group 0.000 claims description 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 23
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 21
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 18
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 17
- 125000001544 thienyl group Chemical group 0.000 claims description 17
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 125000002883 imidazolyl group Chemical group 0.000 claims description 15
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 15
- 125000002252 acyl group Chemical group 0.000 claims description 14
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 14
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 13
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 12
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 12
- 125000004414 alkyl thio group Chemical group 0.000 claims description 11
- 125000001153 fluoro group Chemical group F* 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 9
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 8
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 8
- 125000002837 carbocyclic group Chemical group 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 125000002541 furyl group Chemical group 0.000 claims description 8
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- 238000011321 prophylaxis Methods 0.000 claims description 8
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 8
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 8
- 125000000335 thiazolyl group Chemical group 0.000 claims description 8
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 125000001041 indolyl group Chemical group 0.000 claims description 7
- 208000028867 ischemia Diseases 0.000 claims description 7
- 125000003386 piperidinyl group Chemical group 0.000 claims description 7
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 7
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 206010019280 Heart failures Diseases 0.000 claims description 6
- 125000004423 acyloxy group Chemical group 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000002107 myocardial effect Effects 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 5
- 208000006029 Cardiomegaly Diseases 0.000 claims description 5
- 108091007960 PI3Ks Proteins 0.000 claims description 5
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000005466 alkylenyl group Chemical group 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 201000006370 kidney failure Diseases 0.000 claims description 5
- 229960003966 nicotinamide Drugs 0.000 claims description 5
- 235000005152 nicotinamide Nutrition 0.000 claims description 5
- 239000011570 nicotinamide Substances 0.000 claims description 5
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 5
- 206010039083 rhinitis Diseases 0.000 claims description 5
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims description 5
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 4
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims description 4
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 claims description 4
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 claims description 4
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 4
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims description 4
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 4
- 208000015023 Graves' disease Diseases 0.000 claims description 4
- 125000004171 alkoxy aryl group Chemical group 0.000 claims description 4
- 125000005529 alkyleneoxy group Chemical group 0.000 claims description 4
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 4
- 230000004957 immunoregulator effect Effects 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 4
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 230000007170 pathology Effects 0.000 claims description 4
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 4
- 125000005545 phthalimidyl group Chemical group 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000005493 quinolyl group Chemical group 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 229940124530 sulfonamide Drugs 0.000 claims description 4
- 150000003456 sulfonamides Chemical class 0.000 claims description 4
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 claims description 3
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 125000004442 acylamino group Chemical group 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims description 2
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 206010020880 Hypertrophy Diseases 0.000 claims description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 22
- 230000002265 prevention Effects 0.000 claims 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 3
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 claims 2
- FNLQDVXHDNFXIY-UHFFFAOYSA-N 3h-benzimidazole-5-carboxamide Chemical compound NC(=O)C1=CC=C2NC=NC2=C1 FNLQDVXHDNFXIY-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 1
- URQZZWTWWDIILI-UHFFFAOYSA-N C1=NC(NC(=O)C)=CC=C1C(O)=CC1=NC2=C(Br)C=C(C)C=C2C2=NCCN12 Chemical compound C1=NC(NC(=O)C)=CC=C1C(O)=CC1=NC2=C(Br)C=C(C)C=C2C2=NCCN12 URQZZWTWWDIILI-UHFFFAOYSA-N 0.000 claims 1
- 101150018425 Cr1l gene Proteins 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- WJODTNOONJXHKU-UHFFFAOYSA-N n-(2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-5-hydroxypyridine-3-carboxamide Chemical compound OC1=CN=CC(C(=O)NC=2N3CCN=C3C3=CC=CC=C3N=2)=C1 WJODTNOONJXHKU-UHFFFAOYSA-N 0.000 claims 1
- IJIDTQVVHSOPAF-UHFFFAOYSA-N n-(8,9-dimethoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-5-hydroxypyridine-3-carboxamide Chemical compound N12CCN=C2C=2C=C(OC)C(OC)=CC=2N=C1NC(=O)C1=CN=CC(O)=C1 IJIDTQVVHSOPAF-UHFFFAOYSA-N 0.000 claims 1
- ATMSVZNHDIDXSD-UHFFFAOYSA-N n-(9-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-3h-benzimidazole-5-carboxamide Chemical compound C1=C2NC=NC2=CC(C(=O)NC2=NC3=CC=C(C=C3C3=NCCN32)OC)=C1 ATMSVZNHDIDXSD-UHFFFAOYSA-N 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 208000005189 Embolism Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 4
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 4
- 208000001435 Thromboembolism Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000023328 Basedow disease Diseases 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- 208000012659 Joint disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000038030 PI3Ks Human genes 0.000 description 3
- 108091008611 Protein Kinase B Proteins 0.000 description 3
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 150000003916 phosphatidylinositol 3,4,5-trisphosphates Chemical class 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000036303 septic shock Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 102000011652 Formyl peptide receptors Human genes 0.000 description 2
- 108010076288 Formyl peptide receptors Proteins 0.000 description 2
- 229940125633 GPCR agonist Drugs 0.000 description 2
- 101150089916 Miox gene Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- ZSZXYWFCIKKZBT-ZVDPZPSOSA-N [(2r)-3-[[(2s,3s,5r,6s)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OC1[C@H](O)[C@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O ZSZXYWFCIKKZBT-ZVDPZPSOSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- HKWJHKSHEWVOSS-MRQSADPDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O HKWJHKSHEWVOSS-MRQSADPDSA-N 0.000 description 1
- VYYBOCUNFUHKAD-UHFFFAOYSA-N 1h-pyrrole;quinazoline Chemical compound C=1C=CNC=1.N1=CN=CC2=CC=CC=C21 VYYBOCUNFUHKAD-UHFFFAOYSA-N 0.000 description 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- GONDBTKOFCXMCO-UHFFFAOYSA-N C=1C=CNC=1.N1=CN=CC2=NC=CN=C21 Chemical compound C=1C=CNC=1.N1=CN=CC2=NC=CN=C21 GONDBTKOFCXMCO-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 108091007958 Class I PI3Ks Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- ZINBFGBAIFRYSH-UHFFFAOYSA-N Demethoxyviridin Natural products CC12C(O)C(O)C(=O)c3coc(C(=O)c4c5CCC(=O)c5ccc14)c23 ZINBFGBAIFRYSH-UHFFFAOYSA-N 0.000 description 1
- 101710117072 Dual specificity protein phosphatase Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- FCKJZIRDZMVDEM-UHFFFAOYSA-N N-(7,8-dimethoxy-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene)pyridine-3-carboxamide Chemical compound COC1=C(C2=NC(=NC(=O)C3=CN=CC=C3)N4CCNC4=C2C=C1)OC FCKJZIRDZMVDEM-UHFFFAOYSA-N 0.000 description 1
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 1
- IKRHMBHZYCZSOX-UHFFFAOYSA-N N=1C2=C(OC)C(OC)=CC=C2C2=NCCN2C=1C=C(O)C1=CC=C(NC(C)=O)N=C1 Chemical compound N=1C2=C(OC)C(OC)=CC=C2C2=NCCN2C=1C=C(O)C1=CC=C(NC(C)=O)N=C1 IKRHMBHZYCZSOX-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000013353 Phosphoinositide Phosphatases Human genes 0.000 description 1
- 108010090786 Phosphoinositide Phosphatases Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241001136485 Talaromyces wortmannii Species 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- RQQIRMLGKSPXSE-WIPMOJCBSA-N [1-acetyloxy-2-[[(2s,3r,5s,6s)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxyethyl] acetate Chemical compound CC(=O)OC(OC(C)=O)COP(O)(=O)OC1[C@H](O)[C@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O RQQIRMLGKSPXSE-WIPMOJCBSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- SWJBYJJNDIXFSA-KUHUBIRLSA-N demethoxyviridin Chemical compound O=C1C2=C3CCC(=O)C3=CC=C2[C@]2(C)C3=C1OC=C3C(=O)C[C@H]2O SWJBYJJNDIXFSA-KUHUBIRLSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000026058 directional locomotion Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 125000006277 halobenzyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- DKZHZOKEUAQQSA-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine;1h-pyrrole Chemical compound C=1C=CNC=1.C1=NC=NC2=CC=CN=C21 DKZHZOKEUAQQSA-UHFFFAOYSA-N 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- DDWJFSYHYPDQEL-UHFFFAOYSA-N pyrimidine;1h-pyrrole Chemical class C=1C=CNC=1.C1=CN=CN=C1 DDWJFSYHYPDQEL-UHFFFAOYSA-N 0.000 description 1
- QCDRCGUKNKQTOR-UHFFFAOYSA-N pyrimido[4,5-e]tetrazine;1h-pyrrole Chemical compound C=1C=CNC=1.N1=NN=NC2=NC=NC=C21 QCDRCGUKNKQTOR-UHFFFAOYSA-N 0.000 description 1
- DMFLPSWDPDHHMF-UHFFFAOYSA-N pyrimido[5,4-c]pyridazine;1h-pyrrole Chemical compound C=1C=CNC=1.C1=NC=C2N=NC=CC2=N1 DMFLPSWDPDHHMF-UHFFFAOYSA-N 0.000 description 1
- MOHPKRMFEGZSFP-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine;1h-pyrrole Chemical compound C=1C=CNC=1.N1=CN=CC2=NC=NC=C21 MOHPKRMFEGZSFP-UHFFFAOYSA-N 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02021861 | 2002-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200503306B true ZA200503306B (en) | 2006-07-26 |
Family
ID=32039115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200503306A ZA200503306B (en) | 2002-09-30 | 2005-04-25 | Fused azole-purimidine derivatives |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US7511041B2 (xx) |
| EP (2) | EP1549652B1 (xx) |
| JP (1) | JP4790266B2 (xx) |
| KR (1) | KR101059652B1 (xx) |
| CN (1) | CN100384846C (xx) |
| AR (2) | AR041426A1 (xx) |
| AT (2) | ATE411996T1 (xx) |
| AU (1) | AU2003293310B2 (xx) |
| BR (1) | BRPI0314830B8 (xx) |
| CA (1) | CA2499134C (xx) |
| CY (2) | CY1109790T1 (xx) |
| DE (1) | DE60324296D1 (xx) |
| DK (2) | DK2042504T3 (xx) |
| EC (2) | ECSP055768A (xx) |
| ES (2) | ES2312843T3 (xx) |
| HK (1) | HK1084393A1 (xx) |
| HR (2) | HRP20050375B1 (xx) |
| IL (1) | IL166855A (xx) |
| MA (1) | MA27483A1 (xx) |
| MX (1) | MXPA05001808A (xx) |
| MY (1) | MY140756A (xx) |
| NO (1) | NO331457B1 (xx) |
| NZ (1) | NZ539062A (xx) |
| PE (1) | PE20050089A1 (xx) |
| PL (1) | PL226562B1 (xx) |
| PT (2) | PT1549652E (xx) |
| RU (1) | RU2326881C9 (xx) |
| SI (2) | SI1549652T1 (xx) |
| TW (1) | TWI327570B (xx) |
| UA (1) | UA82205C2 (xx) |
| UY (1) | UY28001A1 (xx) |
| WO (1) | WO2004029055A1 (xx) |
| ZA (1) | ZA200503306B (xx) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| CN102718665B (zh) | 2003-08-29 | 2015-09-16 | 三井化学株式会社 | 农园艺用杀虫剂的制备中间体 |
| DK1761540T3 (en) | 2004-05-13 | 2016-11-21 | Icos Corp | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase DELTA |
| MX2007004051A (es) | 2004-10-07 | 2007-05-24 | Boehringer Ingelheim Int | Pi3-quinasas. |
| WO2006040645A1 (en) * | 2004-10-11 | 2006-04-20 | Ranbaxy Laboratories Limited | N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma |
| EP2360278A1 (en) | 2005-04-14 | 2011-08-24 | Trustees Of Boston University | Diagnostic for lung disorders using class prediction |
| WO2007016979A2 (en) * | 2005-07-29 | 2007-02-15 | 4Sc Ag | NOVEL HETEROCYCLIC NF-κB INHIBITORS |
| US7691868B2 (en) | 2006-04-06 | 2010-04-06 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-quinazoline |
| US7517995B2 (en) | 2006-04-06 | 2009-04-14 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-cyclopentapyrazole |
| KR101422301B1 (ko) * | 2006-04-26 | 2014-07-30 | 에프. 호프만-라 로슈 아게 | 약학적 화합물 |
| WO2008064244A2 (en) * | 2006-11-20 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Phosphoinositide modulation for the treatment of neurodegenerative diseases |
| AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| EP1953163A1 (en) | 2007-02-01 | 2008-08-06 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pteridinone derivatives as PI3-kinases inhibitors |
| WO2008148023A2 (en) * | 2007-05-23 | 2008-12-04 | Medical College Of Georgia Research Institute, Inc. | Compositions and methods for treating neurological disorders |
| JP2010539239A (ja) * | 2007-09-17 | 2010-12-16 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害剤としてのピリドピリミジン誘導体 |
| WO2009039457A1 (en) | 2007-09-19 | 2009-03-26 | The Trustees Of Boston University | Identification of novel pathways for drug development for lung disease |
| CA2713388C (en) * | 2008-01-14 | 2016-03-29 | William Scott | Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| EP2250160B1 (en) | 2008-01-25 | 2015-11-11 | Millennium Pharmaceuticals, Inc. | Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| WO2009111547A1 (en) * | 2008-03-04 | 2009-09-11 | Wyeth | 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis |
| WO2009128520A1 (ja) * | 2008-04-18 | 2009-10-22 | 塩野義製薬株式会社 | Ｐ１３ｋ阻害活性を有する複素環化合物 |
| WO2009155527A2 (en) * | 2008-06-19 | 2009-12-23 | Progenics Pharmaceuticals, Inc. | Phosphatidylinositol 3 kinase inhibitors |
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| EP2168582A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
| US8791131B2 (en) * | 2008-09-30 | 2014-07-29 | Pfizer Inc. | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions |
| EP2364983B1 (en) * | 2008-11-11 | 2013-10-23 | Jeil Pharmaceutical Co., Ltd. | Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same |
| PT2355828T (pt) | 2008-11-13 | 2018-07-02 | Gilead Calistoga Llc | Terapias para malignidades hematológicas |
| US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
| US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
| CA2750935A1 (en) * | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and their use as pi3k inhibitors |
| US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| BRPI1012333A2 (pt) | 2009-03-24 | 2016-03-29 | Gilead Calistoga Llc | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso |
| ES2548253T3 (es) | 2009-04-20 | 2015-10-15 | Gilead Calistoga Llc | Métodos para el tratamiento de tumores sólidos |
| CA2759476C (en) * | 2009-04-30 | 2018-10-09 | Julie Nicole Hamblin | Novel compounds |
| WO2011011550A1 (en) | 2009-07-21 | 2011-01-27 | Calistoga Pharmaceuticals Inc. | Treatment of liver disorders with pi3k inhibitors |
| CA2773848A1 (en) * | 2009-09-09 | 2011-03-17 | Avila Therapeutics, Inc. | Pi3 kinase inhibitors and uses thereof |
| EA201201414A8 (ru) | 2010-04-16 | 2013-12-30 | Байер Интеллектчуал Проперти Гмбх | КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ |
| US9062038B2 (en) | 2010-08-11 | 2015-06-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| EP2621486A1 (en) | 2010-10-01 | 2013-08-07 | Bayer Intellectual Property GmbH | Substituted n-(2-arylamino)aryl sulfonamide-containing combinations |
| EP2638044B1 (en) | 2010-11-11 | 2017-08-30 | Bayer Intellectual Property GmbH | Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
| EP2638043B1 (en) * | 2010-11-11 | 2017-06-07 | Bayer Intellectual Property GmbH | Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines |
| UA113280C2 (xx) | 2010-11-11 | 2017-01-10 | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ | |
| EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| JO3733B1 (ar) | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
| KR20140133590A (ko) | 2012-03-05 | 2014-11-19 | 길리아드 칼리스토가 엘엘씨 | (s)-2-(1-(9h-퓨린-6-일아미노)프로필)-5-플루오로-3-페닐퀴나졸린-4(3h)-온의 다형체 형태 |
| EP3626308A1 (en) | 2013-03-14 | 2020-03-25 | Veracyte, Inc. | Methods for evaluating copd status |
| MX2015011899A (es) | 2013-03-15 | 2016-05-05 | Genentech Inc | Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer. |
| CA2908776C (en) | 2013-04-08 | 2021-08-10 | Bayer Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas |
| CN110003178B (zh) | 2013-05-01 | 2022-02-25 | 豪夫迈·罗氏有限公司 | 二杂芳基化合物及其用途 |
| WO2015027431A1 (en) | 2013-08-29 | 2015-03-05 | Merck Sharp & Dohme Corp. | 2,2-difluorodioxolo a2a receptor antagonists |
| NZ736970A (en) | 2013-12-20 | 2018-11-30 | Gilead Calistoga Llc | Process methods for phosphatidylinositol 3-kinase inhibitors |
| AU2014364414A1 (en) | 2013-12-20 | 2016-06-30 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one |
| CN106459005A (zh) | 2014-06-13 | 2017-02-22 | 吉利德科学公司 | 磷脂酰肌醇3‑激酶抑制剂 |
| US20170335396A1 (en) | 2014-11-05 | 2017-11-23 | Veracyte, Inc. | Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data |
| EP3018131A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| EP3268490B1 (en) | 2015-03-09 | 2020-07-08 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
| CN105130997B (zh) * | 2015-09-25 | 2017-12-05 | 苏州明锐医药科技有限公司 | 一种库潘尼西的制备方法 |
| CN105130998B (zh) * | 2015-09-25 | 2017-07-28 | 苏州立新制药有限公司 | 库潘尼西的制备方法 |
| CN108884098B (zh) * | 2016-03-08 | 2021-09-14 | 拜耳制药股份公司 | 2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类 |
| EP3219329A1 (en) | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
| US10927417B2 (en) | 2016-07-08 | 2021-02-23 | Trustees Of Boston University | Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions |
| CA3037626A1 (en) | 2016-09-23 | 2018-03-29 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
| CA3045041A1 (en) | 2016-12-14 | 2018-06-21 | Tarveda Therapeutics, Inc. | Hsp90-targeting conjugates and formulations thereof |
| EP3585437B1 (en) | 2017-02-24 | 2022-12-21 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib with anti-pd-1 antibody |
| US11185549B2 (en) | 2017-06-28 | 2021-11-30 | Bayer Consumer Care Ag | Combination of a PI3K-inhibitor with an androgen receptor antagonist |
| EP3498266A1 (en) | 2017-12-15 | 2019-06-19 | Bayer Consumer Care AG | Formulations of copanlisib |
| CU24607B1 (es) | 2017-09-08 | 2022-06-06 | Bayer Consumer Care Ag | Sólido estable, liofilizado, que contiene copanlisib, útil para dilución y aplicaciones terapéuticas |
| MX2020003126A (es) * | 2017-09-20 | 2020-10-01 | Abm Therapeutics Corp | Derivados de iminopirimidina ciclicos como inhibidores de cinasa. |
| US11351156B2 (en) | 2017-10-13 | 2022-06-07 | Inserm | Combination treatment of pancreatic cancer |
| WO2019101871A1 (en) | 2017-11-23 | 2019-05-31 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | A new marker for predicting the sensitivity to pi3k inhibitors |
| WO2019105734A1 (en) | 2017-11-28 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib |
| WO2019105835A1 (en) | 2017-11-29 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib and anetumab ravtansine |
| WO2019197269A1 (en) | 2018-04-11 | 2019-10-17 | Bayer Aktiengesellschaft | Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer |
| WO2020020385A1 (zh) * | 2018-07-27 | 2020-01-30 | 上海翰森生物医药科技有限公司 | 含三并环类衍生物抑制剂、其制备方法和应用 |
| CN109053554B (zh) * | 2018-08-01 | 2020-07-28 | 江苏八巨药业有限公司 | 一种使用催化剂合成3-乙酰吡啶的方法 |
| CA3110754A1 (en) | 2018-08-28 | 2020-03-05 | Bayer As | Combination of pi3k-inhibitors and targeted thorium conjugates |
| CA3116230A1 (en) | 2018-10-16 | 2020-04-23 | Bayer Aktiengesellschaft | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |
| CA3118493A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
| BR112021011894A2 (pt) | 2018-12-21 | 2021-09-08 | Daiichi Sankyo Company, Limited | Composição farmacêutica |
| WO2020164997A1 (en) | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combination of pi3k-inhibitors |
| CN114621236A (zh) * | 2022-04-25 | 2022-06-14 | 河南湾流生物科技有限公司 | 一种喹啉类饲料添加剂的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3644354A (en) | 1968-09-16 | 1972-02-22 | Sandoz Ag | 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines |
| US4287341A (en) | 1979-11-01 | 1981-09-01 | Pfizer Inc. | Alkoxy-substituted-6-chloro-quinazoline-2,4-diones |
| CN1033644C (zh) * | 1993-01-02 | 1996-12-25 | 瑞安大药厂股份有限公司 | 3-取代甲基-2，3-二氢咪唑并[1，2-c]喹唑啉衍生物，其制备与用途 |
| RU2203669C2 (ru) | 1994-08-12 | 2003-05-10 | Про-Нейрон Инк. | Способы лечения сепсиса и воспалений с помощью оксипуриновых нуклеозидов |
| AU709190B2 (en) * | 1996-01-29 | 1999-08-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Dihydropyridine-, pyridine-, benzopyran- one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists |
| US5932584A (en) * | 1997-05-06 | 1999-08-03 | National Science Council | Optically active 2,3-dihydroimidazo(1,2-C) quinazoline derivatives, the preparation and antihypertensive use thereof |
| SI2223922T1 (sl) | 2000-04-25 | 2016-04-29 | Icos Corporation | Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme |
| CN100345830C (zh) * | 2000-04-27 | 2007-10-31 | 安斯泰来制药有限公司 | 稠合杂芳基衍生物 |
-
2003
- 2003-09-18 ES ES03788908T patent/ES2312843T3/es not_active Expired - Lifetime
- 2003-09-18 NZ NZ539062A patent/NZ539062A/en not_active IP Right Cessation
- 2003-09-18 MX MXPA05001808A patent/MXPA05001808A/es active IP Right Grant
- 2003-09-18 KR KR1020057005434A patent/KR101059652B1/ko active IP Right Grant
- 2003-09-18 WO PCT/EP2003/010377 patent/WO2004029055A1/en active Application Filing
- 2003-09-18 DK DK08075839.4T patent/DK2042504T3/da active
- 2003-09-18 DK DK03788908T patent/DK1549652T3/da active
- 2003-09-18 DE DE60324296T patent/DE60324296D1/de not_active Expired - Lifetime
- 2003-09-18 RU RU2005113165/04A patent/RU2326881C9/ru active
- 2003-09-18 US US10/527,376 patent/US7511041B2/en active Active
- 2003-09-18 EP EP03788908A patent/EP1549652B1/en not_active Expired - Lifetime
- 2003-09-18 ES ES08075839T patent/ES2367141T3/es not_active Expired - Lifetime
- 2003-09-18 EP EP08075839A patent/EP2042504B1/en not_active Expired - Lifetime
- 2003-09-18 CA CA2499134A patent/CA2499134C/en not_active Expired - Lifetime
- 2003-09-18 AT AT03788908T patent/ATE411996T1/de active
- 2003-09-18 AT AT08075839T patent/ATE511510T1/de active
- 2003-09-18 PL PL375935A patent/PL226562B1/pl unknown
- 2003-09-18 UA UAA200504176A patent/UA82205C2/uk unknown
- 2003-09-18 SI SI200331490T patent/SI1549652T1/sl unknown
- 2003-09-18 PT PT03788908T patent/PT1549652E/pt unknown
- 2003-09-18 SI SI200332036T patent/SI2042504T1/sl unknown
- 2003-09-18 PT PT08075839T patent/PT2042504E/pt unknown
- 2003-09-18 BR BRPI0314830A patent/BRPI0314830B8/pt active IP Right Grant
- 2003-09-18 AU AU2003293310A patent/AU2003293310B2/en not_active Expired
- 2003-09-18 JP JP2004538935A patent/JP4790266B2/ja not_active Expired - Lifetime
- 2003-09-18 CN CNB038233673A patent/CN100384846C/zh not_active Expired - Lifetime
- 2003-09-29 TW TW092126767A patent/TWI327570B/zh not_active IP Right Cessation
- 2003-09-29 PE PE2003000986A patent/PE20050089A1/es active IP Right Grant
- 2003-09-29 AR ARP030103542A patent/AR041426A1/es active IP Right Grant
- 2003-09-29 UY UY28001A patent/UY28001A1/es active IP Right Grant
- 2003-09-29 MY MYPI20033701A patent/MY140756A/en unknown
-
2005
- 2005-02-14 IL IL166855A patent/IL166855A/en active IP Right Grant
- 2005-04-25 ZA ZA200503306A patent/ZA200503306B/en unknown
- 2005-04-27 NO NO20052076A patent/NO331457B1/no not_active IP Right Cessation
- 2005-04-27 HR HRP20050375AA patent/HRP20050375B1/hr not_active IP Right Cessation
- 2005-04-28 EC EC2005005768A patent/ECSP055768A/es unknown
- 2005-04-29 MA MA28247A patent/MA27483A1/fr unknown
-
2006
- 2006-04-19 HK HK06104675.8A patent/HK1084393A1/xx not_active IP Right Cessation
-
2009
- 2009-01-09 CY CY20091100017T patent/CY1109790T1/el unknown
- 2009-03-30 US US12/414,257 patent/US8129386B2/en not_active Expired - Lifetime
- 2009-07-01 AR ARP090102458A patent/AR072458A2/es not_active Application Discontinuation
-
2011
- 2011-02-07 EC EC2011005768A patent/ECSP11005768A/es unknown
- 2011-08-10 CY CY20111100771T patent/CY1112174T1/el unknown
-
2013
- 2013-12-04 HR HRP20131159A patent/HRP20131159B1/hr not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200503306B (en) | Fused azole-purimidine derivatives | |
| EP2638045B1 (en) | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| ES2930157T3 (es) | Combinación que comprende un inhibidor de MEK y un inhibidor de B-Raf | |
| CN100465173C (zh) | 选择性激酶抑制剂 | |
| AU2005245875B2 (en) | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | |
| TW201819386A (zh) | Shp2磷酸酶抑制劑及其使用方法 | |
| CN105682658A (zh) | 使用pi3激酶亚型调节剂的癌症疗法 | |
| KR20080110912A (ko) | 인다졸 화합물 및 ｃｄｃ７의 억제 방법 | |
| ZA200500790B (en) | Substituted quinoline CCR5 receptor antagonists | |
| JP2005500295A (ja) | ホスホジエステラーゼ（ｐｄｅ）７のプリン阻害剤 | |
| EA008241B1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы дельта человека | |
| JP2005506304A (ja) | ホスホジエステラーゼ（ｐｄｅ）７の融合ヘテロ環阻害剤 | |
| JP2020023554A (ja) | ピリミジン化合物及びその医薬用途 | |
| AU2017207291B2 (en) | Methods for the treatment of myeloid derived suppressor cells related disorders | |
| KR20150037877A (ko) | 암, 자가면역성 염증 및 중추신경계 장애를 치료하기 위한 비플루오로디옥살란-아미노-벤즈이미다졸 키나제 억제제 | |
| JP2003515602A (ja) | 免疫抑制薬として有用な２，４−ジアミノピリミジン化合物 | |
| JP2008504303A (ja) | イミダゾロ関連化合物、組成物、及びその使用方法 | |
| JP2017193553A (ja) | 神経線維腫症の処置のためのピリミジルアミノベンズアミド誘導体 | |
| US20100210673A1 (en) | Pyrimidylaminobenzamide derivatives for systemic mastocytosis | |
| JP2007513967A (ja) | 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物 | |
| ES2608585T3 (es) | Derivados de pirimidilaminobenzamida para su uso en el tratamiento de una enfermedad mieloproliferativa inducida por TEL-PDGFRbeta | |
| Schenone et al. | Current advances in the development of anticancer drugs targeting tyrosine kinases of the Src family | |
| JP2008526704A (ja) | ピリド（３，２−ｄ）ピリミジンおよび医療処置に有用な医薬組成物 | |
| TW202320817A (zh) | 用於治療癌症的方法和組成物 |